|
|
 |
|
Viewing report
|
|
|
|
Generics Series: Authorized Generics Analysis
Datamonitor, July 2009, Pages: 76
While the benefits of authorized generics to the branded industry are clearly apparent, the attitude of the generics industry is determined by individual company strategy. For those generics players that aggressively challenge patents, authorized generics are a threat to revenues, while for other smaller companies, authorized generics represent an opportunity to get to market quickly and easily.
Scope
- An overview of the authorized generics landscape, including drivers and resistors for both branded and generics players.
- An insight into which branded and generics companies entered into authorized generics agreements in the US between 2004 and 2008.
- Analysis of the extent of authorized generic market share capture during 2 years following launch, by brand value, therapeutic class, and dosage form.
- An overview into what the future holds for authorized generics, in the US and Europe.
Highlights of this title
Given the benefits associated with own authorized generics, it is unsurprising that these dominated the data-set under investigation, with the Pfizer-Greenstone authorized generic combination by far the most frequent.
The authorized generic launched at a greater discount to the branded drug than the conventional generic, in 65% of agreements under analysis, reflecting the higher margins available to the authorized generics company which potentially neither developed, manufactured, or obtained approval to market the drug.
The greatest number of generic entrants was associated with the highest value branded products (with pre-generic quarterly sales in excess of $600m) in the data-set under analysis, with this group showing an average of 14 and 19 competitors at 1 and 2 years post generics launch.
Key reasons to purchase this title
- Understand what authorized generics are, and the strategic motivations which drive companies to use them.
- Understand the effect of brand value, therapeutic class, and dosage form on the relative success of authorized generics to gain generics market share.
- Gain an insight into how the authorized generics landscape will evolve in the future.
Customers who bought this item also bought
Generic Benchmarking: Brand Erosion at Patent Expiry
Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition
Generic Series: Benchmarking Patent Expiries - Key Factors Affecting Brand Erosion At Patent Expiry
GenericHandbook - A Guide to the Generic Drug Industry in the US
Commercial Insight: Asthma & COPD - On the verge of generic entry
Generic Drug Market in Canada
Forecast Insight: Depression - Generic Induced Brand Erosion Leads to Market Decline
Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition
Booming US Generic Drug Market
Authorized Generics: Look Before you Leap
Special Report: Patterns of Generic Erosion: An International Chartbook, 2008
European Generic Drug Market Potential
|
|
|
|
